Last reviewed · How we verify

Biphemanil — Competitive Intelligence Brief

Biphemanil (DIPHEMANIL) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: diphemanil. Area: Other.

marketed diphemanil Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3 Other Small molecule Live · refreshed every 30 min

Target snapshot

Biphemanil (DIPHEMANIL) — Merck & Co..

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Biphemanil TARGET DIPHEMANIL Merck & Co. marketed diphemanil Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3 1976-01-01
Antrenyl OXYPHENONIUM Novartis marketed oxyphenonium Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4 1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (diphemanil class)

  1. Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biphemanil — Competitive Intelligence Brief. https://druglandscape.com/ci/diphemanil. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: